- Home
- NEXN vs FLGT Comparison
NEXN vs FLGT Comparison
Compare NEXN & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEXN
- FLGT
- Stock Information
- Founded
- NEXN 2007
- FLGT 2011
- Country
- NEXN Israel
- FLGT United States
- Employees
- NEXN N/A
- FLGT N/A
- Industry
- NEXN Computer Software: Programming Data Processing
- FLGT Medical Specialities
- Sector
- NEXN Technology
- FLGT Health Care
- Exchange
- NEXN Nasdaq
- FLGT Nasdaq
- Market Cap
- NEXN 645.6M
- FLGT 683.5M
- IPO Year
- NEXN 2021
- FLGT 2016
- Fundamental
- Price
- NEXN $9.75
- FLGT $17.18
- Analyst Decision
- NEXN Buy
- FLGT Hold
- Analyst Count
- NEXN 6
- FLGT 1
- Target Price
- NEXN $10.33
- FLGT $22.00
- AVG Volume (30 Days)
- NEXN 128.1K
- FLGT 232.2K
- Earning Date
- NEXN 03-05-2025
- FLGT 02-26-2025
- Dividend Yield
- NEXN N/A
- FLGT N/A
- EPS Growth
- NEXN N/A
- FLGT N/A
- EPS
- NEXN 0.09
- FLGT N/A
- Revenue
- NEXN $349,109,000.00
- FLGT $277,761,000.00
- Revenue This Year
- NEXN $7.66
- FLGT N/A
- Revenue Next Year
- NEXN $7.80
- FLGT $16.00
- P/E Ratio
- NEXN $44.21
- FLGT N/A
- Revenue Growth
- NEXN 1.55
- FLGT N/A
- 52 Week Low
- NEXN $4.61
- FLGT $16.36
- 52 Week High
- NEXN $10.94
- FLGT $26.37
- Technical
- Relative Strength Index (RSI)
- NEXN 48.64
- FLGT 40.68
- Support Level
- NEXN $9.21
- FLGT $16.36
- Resistance Level
- NEXN $10.05
- FLGT $17.72
- Average True Range (ATR)
- NEXN 0.27
- FLGT 0.74
- MACD
- NEXN -0.09
- FLGT -0.03
- Stochastic Oscillator
- NEXN 31.41
- FLGT 28.47
About NEXN Nexxen International Ltd. American Depository Shares
Nexxen International Ltd empowers advertisers, agencies, publishers, and broadcasters to utilize video and connected TV. It is a demand-side platform (DSP), supply-side platform (SSP), ad server, and data management platform (DMP) and also delivers a flexible and unified technology stack with advanced and exclusive data at its core.
About FLGT Fulgent Genetics Inc.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.